Premium
LAP‐BAND ® for Lower BMI: 2‐Year Results from the Multicenter Pivotal Study
Author(s) -
Michaelson Robert,
Murphy Diane K.,
Gross Todd M.,
Whitcup Scott M.
Publication year - 2013
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1002/oby.20477
Subject(s) - medicine , dyslipidemia , weight loss , clinical endpoint , prospective cohort study , body mass index , quality of life (healthcare) , adverse effect , diabetes mellitus , weight change , cohort , obesity , clinical trial , endocrinology , nursing
Objective The goal of this study was to examine the safety and effectiveness of the LAP‐BAND ® System for patients with 30‐39.9 BMI and associated comorbidities. Design and Methods In this prospective, multicenter, interventional cohort study, subjects with a BMI between 30 and 39.9 who had failed prior weight loss attempts were recruited from 7 surgical centers. The primary effectiveness endpoint required that >40% of subjects achieve ≥30% excess weight loss (EWL) at 1 year. Secondary endpoints included assessment of comorbidities and quality‐of‐life. Results Of 149 subjects, 90.6% were female, with mean BMI of 35.3kg/m 2 . At 1 year, 84.6% of subjects achieved ≥30% EWL ( P < 0.0001), with 65.0% mean EWL; 66.4% of subjects were no longer obese (BMI < 30). Baseline comorbidities improved at 1 year for 64.4% with dyslipidemia, 59.6% with hypertension, and 85.7% with diabetes. Quality‐of‐life (IWQOL‐Lite) also improved ( P < 0.0001). The Year 1 results were maintained or improved at 2 years. Regression analysis indicates that each additional 10% weight loss at Year 2 was associated with an increase in IWQOL‐Lite by 7.1 points and a decrease in triglycerides by 13.7 mg/dL, fasting glucose by 3.5 mg/dL, and systolic blood pressure by 3.3 mmHg. Most adverse events were mild to moderate and resolved without sequelae within 1 month. Five subjects (3.4%) had explantations. Conclusion LAGB is safe and effective for people with 30‐39.9 BMI, with weight loss and comorbidity improvement through at least 2 years.